Signoretti Lab

We are looking for a JUNIOR PATHOLOGIST (at least 1 year of residency training) to join our group and lead one of our translational efforts in kidney cancer. Please contact us if you are interested and willing to spend at least 2 years in the lab.

Wrapping #kcrs24! Started my day with rock the run 5k and finished it with insightful discussions and inspiring moments. So glad to be part of kidney cancer research but also part of a great team along the way of curing this cancer!

Many congratulations Berkay Simsek for being a recipient of the KCRS 2025 Merit Awards for Translational Research @simsek_berkay_ @kidneycan @MassGenBrigham #KCRS25 #kidneycancer

The #KCRS2025 ⁦@kidneycan⁩ is also about ART!

#KCRS25 Oral Abstract: @simsek_berkay_ @BrighamWomens links CD163+ macrophages in RCC tumors to better outcomes with nivolumab. A potential new target for immunotherapy. Read all the abstracts: bit.ly/AbstractsKCRS25 Register: bit.ly/RegisterKCRS25 #AcceleratingCures

Pathologist representation at this year’s #KCRS25, one of my most important and favorite meetings each year. 🔬🩺🩻 #gupathology #workingtogethertofightRCC @PayalKapur5 @Unclassified1 @drmehrarohit @kidneycan @OncoAlert @urotoday

So proud to be part of this incredible research team! #KCRS25 #pathology #kidneycancer @kidneycan

Thanks to our friends at Cure Today for letting me share some advice for new patients. 👊👊 ⁦@DanaFarber⁩ ⁦@DrChoueiri⁩ ⁦@DanaFarber_GU⁩ ⁦@kidneycan⁩ ⁦@TheJimmyFund⁩ ⁦@DanaFarberNews⁩ curetoday.com/view/finding-s…

Celebrating Dr Sabina Signoretti @BrighamWomens work and dedication over the years to @DanaFarber @BrighamWomens @df_hcc Pathology! cc: @LabSignoretti @kaelin_lab @harvardmed

Phase 1/2 Design of the HIF2a inhibitor NKT2152-101 showed response rate of 20% with an ‘in class’ toxicity profile #ESMO24 . The long half like makes it distinct and there in now a dose to take to randomised trials. Advantages over belzurifan are unclear. 2 doses being pursued.

Sarcomatoid RCC #kidneycancer : Diagnostic Updates and Therapeutic Implications. Comprehensive talk by @SabinaSign16728 @BrighamWomens 👉epigenomics, genetics and inflammed phenotype of Sarcomatoid RCC & Rx implications #KCRS24 @kidneycan @DrChoueiri @TalalZarif1 @OncoAlert

Kicking off the Trials in Progress session with #ARCITECT evaluating Botensilimab+Balstilimab for pts with mRCC A trial that aims to "raise the tail" and a fantastic presentation by @MikeSerzanMD #KCRS24 @kidneycan @OncoAlert

Great work from these presenters!

The #INTerpath-004 trial explores the combination of pembro + personalized mRNA #vaccine for the adjuvant treatment of pts with RCC. Inspiring talk by @DrChoueiri at #KCRS24! @kidneycan @DanaFarber_GU @OncLive

🟢 Outstanding presentation at #KCRS24 @drmehrarohit 🟠 Role of Pathologist in Kidney Cancer Diagnostics and Research 🟠 Highlighting the morphologic diversity in renal tumors and its diagnostic implications. 🟠 Emphasis on understanding mechanisms to improve patient care.…

We are super interested in the IVC thrombus @UTSWUrology @utswcancer @UTSWHemeOnc! @PayalKapur5 shows IVC correlates and Angioscore for as a biomarker for angiogenic driven tumor. @KCPUTSW #KCRS24 @kidneycan

Thank you Chuck for sharing! It’s very inspiring! Advocacy, research, and patient care unite to accelerate the cure! We can’t do it alone – we need each other! @kidneycan @DrChoueiri @advocatekidneys #KCRS24 @OncoAlert @CJSTRAV3 #Advocate @HHammersMD @neerajaiims @yekeduz_emre…

Brilliant insights from @tompowles1 @QMBCI. Excellent use of Twitter polls to reconcile tough clinical scenarios (eg IO rechallenge following adj pembro). Shocking to hear rates of IO receipt in real world series - great point from Tom - use the best tx first. @DrChoueiri…

#KCRS24 Session 8: Rapid Abstract Presentations are underway! Tertiary Lymphoid Structures in Sarcomatoid RCC @NickSalgia Brain-Specific Tropism in mRCC @rmelias2 Latino Ethnicity & Gut Microbiome in mRCC @ReginaBarCar #KidneyCancer #AcceleratingCures